



Involvement of a non-human sialic acid in human cancer

Annie N. Samraj[†], Heinz Läubli[†], Nissi Varki and Ajit Varki*

Departments of Medicine, Pathology and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA

Edited by:

Adriane Regina Todeschini,
Universidade Federal do Rio de
Janeiro, Brazil

Reviewed by:

Stephan Von Gunten, University of
Bern, Switzerland
Daniel Christian Hoessli, International
Center for Chemical and Biological
Sciences, Switzerland

*Correspondence:

Ajit Varki, Departments of Medicine,
Pathology and Cellular and Molecular
Medicine, Glycobiology Research and
Training Center, University of
California San Diego, La Jolla, CA
92093, USA
e-mail: a1varki@ucsd.edu

[†] Annie N. Samraj and Heinz Läubli
have contributed equally to this work.

Sialic acids are common monosaccharides that are widely expressed as outer terminal units on all vertebrate cell surfaces, and play fundamental roles in cell–cell and cell–microenvironment interactions. The predominant sialic acids on most mammalian cells are *N*-glycolylneuraminic acid (Neu5Gc) and *N*-acetylneuraminic acid (Neu5Ac). Neu5Gc is notable for its deficiency in humans due to a species-specific and species-universal inactivating deletion in the *CMAH* gene encoding the hydroxylase that converts CMP-Neu5Ac to CMP-Neu5Gc. However, Neu5Gc is metabolically incorporated into human tissues from dietary sources (particularly red meat), and detected at even higher levels in some human cancers. Early life exposure to Neu5Gc-containing foods in the presence of certain commensal bacteria that incorporate dietary Neu5Gc into lipooligosaccharides can lead to generation of antibodies that are also cross-reactive against Neu5Gc-containing glycans in human tissues (“xeno-autoantigens”). Such anti-Neu5Gc “xeno-autoantibodies” are found in all humans, although ranging widely in levels among individuals, and displaying diverse and variable specificities for the underlying glycan. Experimental evidence in a human-like Neu5Gc-deficient *Cmah*^{−/−} mouse model shows that inflammation due to “xenosialitis” caused by this antigen–antibody interaction can promote tumor progression, suggesting a likely mechanism for the well-known epidemiological link between red meat consumption and carcinoma risk. In this review, we discuss the history of this field, mechanisms of Neu5Gc incorporation into tissues, the origin and specificities of human anti-Neu5Gc antibodies, their use as possible cancer biomarkers, implications of xenosialitis in cancer initiation and progression, and current and future approaches toward immunotherapy that could take advantage of this unusual human-specific phenomenon.

Keywords: Neu5Gc, sialic acid, antibodies, inflammation, tumor antigen, red meat

HISTORICAL BACKGROUND

Nearly 100 years ago, Hanganutziu and Deicher independently described human heterophile antibodies that agglutinated animal erythrocytes, as occurring in patients with serum-sickness, who had received therapeutic animal antisera (1, 2). Similar antibodies were later reported in patients with various diseases, despite no prior exposure to animal serum (3). Characterization of the antigenic determinants of these Hanganutziu–Deicher (H–D) antibodies occurred when Higashi et al. and Merrick et al. demonstrated that at least some of the major epitopes recognized were gangliosides containing a sialic acid (Sia) called *N*-glycolylneuraminic acid (Neu5Gc) (4, 5). This discovery spurred further research and H–D antibodies were also described in sera from patients with multiple pathological states such as rheumatoid arthritis, infectious mononucleosis, leprosy, syphilis, leukemia, Kawasaki disease, and various cancers (6–17). Expression of Neu5Gc on gangliosides and glycoproteins of human meconium and various human tumors was also detected by immunohistochemistry or thin-layer chromatography using polyclonal chicken antibodies raised against Neu5Gc-containing ganglioside GM3, or indirectly, via inhibition of bovine erythrocyte agglutination by a human H–D antiserum (10, 18–32). Given the data available at the time, it was reasonable to assume that Neu5Gc was an “oncofetal

antigen,” expressed in fetal tissues, suppressed in adult life, and later up regulated during carcinogenesis. However, the evidence for an immune response raised questions about this assumption. In retrospect, the early reports of H–D antigens in cultured human cancer cell lines was probably due to animal serum used in the medium, and those in human cancer samples were likely of dietary origin (see below).

DIVERSITY IN THE SIALIC ACIDS

Classic studies of the structure, chemistry, and biosynthesis of sialic acids (Sias) occurred in parallel with the discovery and characterization of H–D antibodies. Sialic acids are a large family of nine-carbon-backbone monosaccharides primarily expressed in animals of the Deuterostome lineage (33, 34). They are most commonly found as the terminal units of the dense glycoconjugate coat covering cell surfaces, and of glycan chains attached to secreted molecules. By virtue of their position and high expression, Sias frequently act as the interface between the cell and the extracellular environment and mediate key roles such as stabilization of molecules and membranes via negative charge and hydrophilicity, transmembrane signaling, and receptor functions for self and non-self ligands (35, 36). They are also remarkably diverse owing to the various possible permutations involving different α -linkages

between C-2 and the underlying glycan chain, as well as a variety of natural modifications. The predominant types of Sias in mammals include *N*-acetylneuraminic acid (Neu5Ac) and its hydroxylated version, Neu5Gc (**Figure 1**). These two molecules differ by a single oxygen atom, which is added to CMP-Neu5Ac in the cytosol, via a reaction catalyzed by the enzyme cytidine monophosphate *N*-acetylneuraminic acid hydroxylase (CMAH) (37–44). These activated sugars are then transported into the Golgi, where they act as donors for various sialyltransferases. (45).

HUMAN DEFICIENCY OF Neu5Gc BIOSYNTHESIS


Following the reports of Neu5Gc in fetal and malignant tissues, it was found that all humans are homozygous for an Alu-mediated deletion of exon 6 in the *CMAH* gene, which results in a truncated, inactive enzyme (46–48). We can only speculate if positive or negative selection was involved in the fixation of this mutation in the human lineage. Negative selection by a lethal infectious pathogen that preferred Neu5Gc as a binding target is a possibility (49). Positive selection due a fertility advantage to Neu5Gc-negative females could also have been operative (50). Alternatively, the human condition may simply be the result of a random mutation that became fixed in a small population that eventually gave rise to modern humans. Regardless of these considerations, this rather drastic change in the sialic acid topology of the cell surface can be dated back to ~2–3 mya, prior to the origin of the genus *Homo*, and may even have been involved in the origin of the genus (50). Not only has there been a corresponding increase in the precursor Neu5Ac, but also multiple related changes in Sia biology and pathogen regimes, which are discussed elsewhere (51, 52).


Since Neu5Gc has been found in many species of the deuterostome lineage (ranging from sea urchins to fish to non-human primates), the *CMAH* gene is at least 500 million years old (53). Notably, Neu5Gc deficiency seems to have evolved independently

in sauropsids (birds and reptiles) and possibly in monotremes such as the platypus (53). Indeed, chickens are similar to humans in recognizing Neu5Gc as a foreign antigen and mounting a strong immune response against it. A serum-sickness like condition can be induced when horse serum is injected into chickens or by the virally induced Marek's disease, a lymphoma that expresses Neu5Gc by unknown mechanisms (54–57).

Neu5Gc CAN BE METABOLICALLY INCORPORATED INTO HUMAN TISSUES FROM DIETARY SOURCES

Until the end of the last century, the evidence for Neu5Gc in human tissues remained indirect, based on polyclonal antibodies raised in chickens or using H–D antibodies from human patients (26, 32). In order to confirm the findings of the classic studies that showed the oncofetal expression pattern of Neu5Gc, a chicken anti-Neu5Gc IgY with high specificity and avidity was generated by affinity purification and it indeed detected accumulation of Neu5Gc in human tumors such as breast carcinomas, in fetal epithelial cells, and in placental endothelial cells (**Figure 2**) (58). Surprisingly, small but definite amounts of Neu5Gc were also detected in normal human secretory epithelia and on endothelia of small- and large-blood vessels. These findings were supported by mass-spectrometry analysis of purified sialic acids (58) and of *N*-glycans released from human tumor samples (59). Subsequent studies of *Cmah*^{−/−} mice showed a complete absence of Neu5Gc (59), indicating that there is no alternate pathway for the *de novo* biosynthesis of Neu5Gc. In the absence of any other explanation, it was concluded that Neu5Gc must be entering human tissues exogenously via oral ingestion. Dietary sources that are rich in Neu5Gc include red meats such as beef, pork, lamb, and to a much lesser degree, cow's milk products. Of significant note is the fact that plants and poultry do not contain Neu5Gc, and that fish samples studied so far contain low to trace amounts (58, 60).





Given that Neu5Gc incorporation is practically significant, there is a need for the sensitive and specific detection of Neu5Gc in human and *Cmah*^{-/-} mouse tissues, as well as in biotherapeutic products (see below). There are several immunological and chemical methods to detect such trace amounts of Neu5Gc. **Table 1** summarizes the different methods with description of advantages and disadvantages of each. Immunodetection with a polyclonal anti-Neu5Gc IgY was among the first methods employed for the detection of Neu5Gc in tissues. Polyclonal antibodies are able to broadly detect epitopes with a terminating Neu5Gcα2-R unit, whereas the various monoclonal antibodies are very specific for different Neu5Gc-containing gangliosides. While such antibodies (and newer versions that are more specific) are commonly applied to immunohistochemical techniques now, certain caveats apply. Gangliosides can be lost in the paraffin-embedding process, therefore, frozen section analysis is preferred. Strong binding to endothelial Neu5Gc maybe used as a positive control and negative control can include competitive inhibition with a Neu5Gc-containing reagent such as 10% chimpanzee serum, mild periodate oxidation of the sialic acid chain, or sialidase treatment of tissue sections. Each approach has pros and cons and must be properly controlled.

MECHANISMS FOR METABOLIC INCORPORATION OF Neu5Gc INTO *Cmah* NULL CELLS AND TISSUES

In vitro evidence shows that cultured human epithelial cells can incorporate Neu5Gc into endogenous glycoproteins from animal products (such as fetal calf serum) in the medium. Incorporation of Neu5Gc involves fluid-phase pinocytosis to enter the lysosome, where a sialidase releases Neu5Gc from glycoconjugates, and a sialic acid transporter then delivers the foreign sialic acid to the cytosol. Free Neu5Gc in the extracellular fluid can follow the

same pathway (61). Cytosolic Neu5Gc now becomes available for activation to CMP-Neu5Gc in the nucleus and is subsequently transported into the Golgi. Evidently, the single oxygen atom difference between the foreign Neu5Gc and the native Neu5Ac remains permissive for the human sialic biosynthetic machinery, which utilizes Neu5Gc as if it were a “self” molecule (61, 62).

With regard to the intact organism, few studies had investigated the fate of orally ingested Neu5Gc in mammals. Nöhle and Schauer first showed that radioactive free sialic acid fed to mice and rats appeared in urine and was metabolized, as a portion of the radioactivity was recovered as expired CO₂ (63–65). Radioactivity from labeled sialic acids in mucins was also detected in murine tissues after oral gavage (65). Oral ingestion studies in normal adult humans showed that free Neu5Gc can be absorbed and excreted within 4–6 h and detected only in trace amounts in salivary mucins and facial hair (58). The generation of a *Cmah*^{-/-} mouse in 2007 paved the way to further investigate the consequences of Neu5Gc deficiency (66). Using this human-like Neu5Gc-deficient mouse, it was shown that this foreign Sia can indeed masquerade as a self-molecule and be incorporated in normal healthy tissues, into the fetus, and into cancers (67). In these mice, free Neu5Gc (i.e., the monosaccharide) can be rapidly absorbed into circulation with peak levels seen at 1–2 h post ingestion and is efficiently excreted by the kidneys. In contrast, oral ingestion of glycosidically bound Neu5Gc (i.e., Neu5Gc-glycoconjugates such as porcine submaxillary mucins) led to incorporation into the small intestinal wall, liver, kidney, and was detectable in the peripheral circulation for several hours (67). Further investigation is necessary to understand the factors affecting the bioavailability of ingested Neu5Gc, the mechanisms behind the selective incorporation of glycosidically bound Neu5Gc, the preferential incorporation into endothelial and epithelial cells, and the eventual metabolic fate

Table 1 | Overview of methods to detect small amounts of Neu5Gc.

Method	Methodological features	Comments ^a
Polyclonal anti-Neu5Gc chicken IgY	Ganglioside GM3(Neu5Gc) as immunogen (54)	Recognizes gangliosides with Neu5Gc α 2-R terminus. Applied to immunohistochemistry and TLC overlays
Affinity-purified polyclonal anti-Neu5Gc chicken IgY	Above polyclonal affinity purified on octyl-sepharose immobilized GM3(Neu5Gc) (157)	Specificity as above, likely cleaner background
Improved affinity-purified polyclonal anti-Neu5Gc chicken IgY	Above polyclonal antibody affinity purified on sequential columns of immobilized human and chimpanzee serum sialoglycoproteins, then eluted with Neu5Gc (158). Original immunogen noted to include bovine serum albumin as stabilizer – actually contaminated with Neu5Gc-rich bovine serum sialoglycoproteins, which acted as additional immunogens	Recognizes terminal Neu5Gc irrespective of linkage or underlying glycan chain (128). Applicable to ELISA, western blot, immunohistochemistry, and flow cytometry. Still contains IgY against animal albumin, removable by adsorption with column of mild periodate-borohydride-treated BSA (unpublished observations)
Monoclonal anti-Neu5Gc chicken IgYs	Monoclonal chicken anti-Neu5Gc IgYs (mChGc6-1, mChGc2-7) (74, 159)	mChGc2-7 has relatively broad specificity, similar to above polyclonal (128). Not yet studied for most applications
Monoclonal anti-Neu5Gc mouse/human IgM or IgG	MK2-34 murine IgM anti-GM2(Neu5Gc) (160), Y2-HD-1, GMR14 murine IgG anti-GM2 (Neu5Gc) (81), 14F7 murine IgG anti-GM3(Neu5Gc) (140), GMR8 murine IgG anti-GM3(Neu5Gc) (161), GMR3 murine IgG anti-GD3(Neu5Gc-Neu5Gc-) (162), YK-3 human IgM against Neu5Gc disialogangliosides (163)	Each specific for different Neu5Gc gangliosides, but will miss many other Neu5Gc epitopes. Gangliosides get extracted from tissues during paraffin-embedding process and can be missed
Detection of sialidase or acid-released free Neu5Gc by HPAE-PAD	High-performance anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD) (164–166)	Purification of released Neu5Gc improves background. Alkaline HPAEC conditions destroy <i>O</i> -acetyl groups
Detection of sialidase or acid-released free Neu5Gc by mass spectrometry	RP-HPLC with tandem MS interfaced with an electrospray ionization source (ESI) (167, 168)	Purification of released Neu5Gc and selective ion monitoring in mass spectrometry improves signal to noise
Detection of derivatized free Neu5Gc (sialidase or acid-released)	Fluorescent labeling with 1,2-diamino-4,5-methylenedioxybenzene (DMB) followed by RP-HPLC (164, 169, 170)	Sensitivity of fluorescence labeling can detect in the pmol range and ultra HPLC (UHPLC) allows run times as short as 10 min. DMB derivatization less likely to change Sia <i>O</i> -acetylation
Mass-spectrometry of glycans carrying Neu5Gc	Released <i>N</i> - or <i>O</i> -Glycan mixtures permethylated to facilitate purification and enhance signal in MALDI-TOF mass spectrometry (59)	Requires specific release of glycans. Alkaline permethylation destroys <i>O</i> -acetyl groups
Neu5Gc specific aptamers	Aptamers screened from a chemically synthesized nucleic acid library by “systematic evolution of ligands by exponential enrichment” (SELEX) (171)	Novel method with high affinity and apparent specificity Not tested on biological samples yet

^a See text for further discussion.

of this foreign molecule in human cells. With regard to the latter issue, recent work has revealed a degradative pathway involving sequential conversion to *N*-glycolylmannosamine (ManNGc), *N*-glycolylglucosamine (GlcNGc), and GlcNGc 6-phosphate, with eventual release of the glycolyl group into cellular metabolic pathways (68). With the exception of the last step, all other reactions are reversible, and little is known about rates of turnover and any other metabolic pathway that may be involved. The same studies also practically ruled out prior suggestions that Neu5Gc expression in humans might originate from an alternate pathway involving glycolyl-CoA (69, 70).

ORIGINS AND IMPLICATIONS OF THE HUMAN IMMUNE RESPONSE AGAINST Neu5Gc

Until the end of the 1990s, anti-Neu5Gc antibodies were thought to be present only in humans who had received therapeutic animal sera injections or those diagnosed with diseases like cancer, but not in normal healthy individuals. However, reports from the xenotransplantation field identified non-Gal antibodies specific for Neu5Gc that were detectable by flow cytometry in the majority of normal healthy humans (71). Parallel studies in our lab showed that the immune response against Neu5Gc was actually universal in humans (58), but of widely ranging levels. The antibodies

were also diverse and of broad polyclonal specificities, arising from selective recognition of the underlying glycan as well (72, 73). The discrepancy with the earlier studies was likely due to the different methods of detection and/or antigens used in the assays. One of the cancer-associated H-D antigens used as the ELISA detection target in earlier studies was the ganglioside GM3(Neu5Gc) (4, 74, 75), an antigen against which antibodies in healthy humans tend to be low. Also, in some studies the antibody binding signal in normal subjects was simply assumed to be non-specific and subtracted as background (30, 76). Further, it was assumed that H-D antibodies were directed against Neu5Gc alone. However, a monosaccharide by itself cannot fill the binding pocket or paratope of the antibody, which can accommodate four to five sugars (77). Thus, the wide range of naturally occurring Neu5Gc-glycoconjugates would warrant a diverse, polyclonal immune response not just against the Sia, but also the underlying glycan (72). Indeed, chemo-enzymatically synthesized α 2-3 or α 2-6 linked sialoside pairs (i.e., identical glycans with either Neu5Gc or Neu5Ac) (78, 79) were used to analyze anti-Neu5Gc antibodies, revealing complex patterns of IgG, IgM, and IgA reactivities with marked variations in the antibody profiles within the normal human population (73). In retrospect, this also explains prior successes in obtaining monoclonal antibodies with specificities for particular Neu5Gc-containing molecules (74, 80–84).

The levels of these naturally occurring polyclonal antibodies can be quite high in some humans, approaching those of the major anti-glycan antibodies in normal human serum: anti-ABO blood group and anti- α -Gal (anti-Gal α 1-3Gal β 1-4GlcNAc) (72). Such antibodies arise from antigenic stimulation by gastrointestinal bacteria and the latter are well known as an immunological barrier for xenotransplantation. In contrast to α -Gal, which is not expressed on human cells, the “xenogenic” Neu5Gc is enriched in cancer cells and can be incorporated into normal vertebrate cells as it is recognized by the biochemical pathways as a self or “autogenic” entity. Thus, Neu5Gc is the first example of a “xeno-autoantigen” (59, 62). Given this incorporation, circulating anti-Neu5Gc antibodies become potentially relevant in the pathogenesis of diseases associated with chronic inflammation such as cancer, atherosclerosis, and autoimmune disease (73, 85).

It was recently shown that anti-Neu5Gc antibodies in humans emerge during the first year of life and are likely not germ-line encoded “natural” antibodies (86). They appear at 6 months and steadily rise to adult levels by 1 year of age. This occurs coincident with the introduction of Neu5Gc via cow’s milk in baby formula. *Cmah*^{-/-} mice were used to study this temporal effect further. A variety of Neu5Gc-feeding paradigms failed to generate anti-Neu5Gc antibodies in these mice. Instead, it was found that commensal non-typeable *Haemophilus influenza* is able to scavenge free dietary Neu5Gc and express it as an immunogenic epitope, thereby effectively “vaccinating” the host to generate anti-Neu5Gc IgM and IgG antibodies (86). It is possible that other commensal or pathogenic bacteria can also carry out this “xeno-autoimmunization,” and it is likely that there are other routes of immunization as well, considering the variable response that is seen across normal individuals. Further investigation is necessary to define the cellular and molecular pathways required for antibody selection, generation, and secretion, the specific B cell

populations responsible, the levels of IgA antibodies in secretions, whether the anti-Neu5Gc response is T cell independent, and whether affinity maturation of the antibody binding site occurs following class-switching.

RED MEAT CONSUMPTION INCREASES CARCINOMA RISK

Diet remains one of the most modifiable risk factors for many chronic diseases including cancer. Although meat is a valuable source of essential amino acids, iron, key vitamins and minerals, numerous epidemiological studies agree that consumption of red meat (meat from mammalian sources such as lamb, pork, and beef), is associated with not only increased risk of certain cancers but also cardiovascular disease (87, 88). Prominent among the large prospective cohorts are the Health Professionals Follow-up Study and the Nurses’ Health Study that recently confirmed that a higher intake of red meat was associated with a significantly elevated risk of cancer, cardiovascular disease, and total mortality (89).

The cancer type that has been most prominently associated with red meat consumption is colorectal cancer (CRC), one of the leading causes of cancer-related deaths in the United States (90). A statistically significant increase in CRC risk of 1.35-fold is seen with a high intake (>160 g/day) of red meat (91). This association is stronger for processed meat than for unprocessed meat. Esophageal, gastric, prostate, and endometrial cancer risk is also significantly elevated by high meat consumption, although conflicting reports exist (92–95). These associations are understandably variable, as diet is difficult to measure accurately, especially given the multiple correlations between different components of food.

There have been several mechanisms proposed by which red meat consumption increases the risk of cancer including: (1) high-fat intake (96); (2) the production of heterocyclic amines and polycyclic aromatic hydrocarbons formed by high temperatures during grilling (97); (3) the presence of mutagenic *N*-nitroso compounds (98); and, (4) the higher levels of heme iron as a promoter of carcinogenesis through increased cellular proliferation, increased oxidative stress, and iron-induced hypoxia signaling (99). The first three mechanisms have been effectively ruled out by epidemiological data, and by the fact that the risk is exclusive for red meat, and not for poultry or fish. More recently, a new mechanism for the link between cardiovascular disease and red meat was proposed to involve the intestinal microbiota. Metabolism of L-carnitine that is abundant in red meat by the microbiota generates trimethylamine-*N*-oxide (TMAO), which is proatherogenic in mice (100) and is associated with increased cardiovascular risk in humans (101). However, no connection of TMAO to cancer risk was reported.

Overall, there is no theory that has been conclusively proven. We propose that “xenosialitis” or the interaction between the non-human Neu5Gc and circulating anti-Neu5Gc results in chronic inflammation that promotes carcinogenesis and atherogenesis. In this regard, red meat consumption and the “western diet” have been associated with increased circulating markers of inflammation in human population studies (102). Thus, Neu5Gc may be the missing link between red meat consumption and risk of cancer and cardiovascular disease, an association that so far appears unique to

humans. Evidence supporting our hypothesis is presented in the further sections.

ROLE OF INFLAMMATION IN CANCER

The mammalian immune system recognizes and eliminates cells with non-native DNA, including transformed cells (103–108). During cancer progression, however, tumor cells can escape elimination by the immune system by being selected for low immunogenicity or by being able to inhibit immune cell activation and induce an immunosuppressive microenvironment (104, 109–111). Some of these pathways can be targeted for cancer immunotherapies (108, 112–114).

In contrast to this immunosurveillance function, inflammation and associated activation of the immune system can also promote cancer progression (115–117). Chronic inflammation due to infectious and non-infectious agents such as auto-inflammatory diseases and diet-induced metabolic syndrome is an important etiology for the development of cancer (116–118). In this regard, epidemiological analyses have confirmed that interference with inflammation using non-steroidal anti-inflammatory drugs including aspirin are protective for the development of inflammation-induced cancers such as colorectal carcinomas (119, 120). Aspirin use has also been associated with reduced incidence of other cancers including those of the esophagus and stomach (121).

Inflammation not only works as promoter during carcinogenesis (inflammation-induced cancer), but growing tumors that escaped immunosurveillance also induce an inflammatory response that can support cancer progression (cancer-related inflammation) (115, 122). In particular, cells from the myeloid lineage such as neutrophils and monocytes/macrophages support cancer progression (110, 123–125). Thus, while the immune system exerts considerable immunosurveillance to eliminate tumor cells, inflammatory pathways can be co-opted by tumor cells to promote cancer progression. Moreover, inflammation can also act as an oncogenic promoter during tumorigenesis, inducing DNA damage via reactive oxygen species.

EXPERIMENTAL STUDIES OF Neu5Gc-INDUCED XENOSIALITIS IN CANCER

Aberrant cell surface glycosylation is a well-known characteristic of cancer and can be altered by the loss or gain of certain structures, the presence of truncated structures, accumulation of precursors, and the synthesis of novel structures (126). Increased cell surface sialylation is one such example. Not only is there an increase in the total sialic acid content, but also significant changes in their modifications such as the accumulation of Neu5Gc. This molecule preferentially accumulates in malignant tissue due to multiple mechanisms, including increased macropinocytosis (61), rapid growth rates, and up-regulation of the sialin transporter in response to hypoxia (127). In keeping with this, subcutaneous syngeneic tumors showed high levels of Neu5Gc incorporation when *Cmah*^{-/-} mice drank water containing Neu5Gc (67), conditions under which normal tissues were not easily loaded.

This accumulation occurs in the presence of circulating xeno-autoantibodies against Neu5Gc-glycans. Different experimental models were used to ask if inflammation mediated by the

anti-Neu5Gc immune response (xenosialitis) could influence tumor growth by affecting cancer-related inflammation (59, 73). *Cmah*^{-/-} mice subcutaneously injected with the low metastatic B16F1 murine melanoma cell line that expresses Neu5Gc on its surface developed antibodies against Neu5Gc and the tumors then grew larger over time (59). Subcutaneously injected murine MC38 tumor cells also formed larger tumors in *Cmah*^{-/-} mice when polyclonal mono-specific murine anti-Neu5Gc antibodies were transferred passively via intraperitoneal injection (59). The increase in tumor growth was associated with enhanced infiltration of cells of the innate immune system, suggesting a role of these cells in promoting effects.

Blunting cancer-related inflammation in the subcutaneous MC38 model with a cyclooxygenase-2 inhibitor repressed the effect of anti-Neu5Gc antibodies (59). However, when higher doses of human anti-Neu5Gc antibodies purified from commercially available human intravenous immunoglobulins (IVIG) were transferred passively into mice by intraperitoneal injection, the growth of subcutaneous syngeneic MC38 tumors was significantly inhibited (73). This finding indicates that Neu5Gc-containing glycans could potentially serve as targets for immunotherapy. Indeed, when Neu5Gc production in MC38 cells was silenced via siRNA targeting the *Cmah* transcript, inhibition by transferred Neu5Gc antibodies was blunted (73). The experimental evidence discussed here indicates that low levels of anti-Neu5Gc antibodies can support cancer progression by enhancing tumor-related inflammation via induction of “xenosialitis,” and that higher doses might possibly be used to target tumors that have high levels of Neu5Gc in their glycocalyx. Further studies of this issue are underway, including models where tumors in mice accumulate Neu5Gc from dietary sources, in a manner similar to the human condition.

CIRCULATING ANTI-Neu5Gc ANTIBODIES AS TUMOR MARKERS

Earlier studies discussed above had reported an increased incidence of H–D antibodies in patients with cancer. Sera of patients with cancer were therefore analyzed for the presence of anti-Neu5Gc antibodies with specificity toward different Neu5Gc-glycan epitopes (73). A sialoglycan microarray of over 70 chemoenzymatically synthesized sialoglycans including unique pairs of Neu5Gc- and Neu5Ac-containing glycans were used to analyze the different binding properties of antibodies from patients with breast cancer versus controls in order to identify a classifier of 20 Neu5Gc-containing glycans (73). Using these 20 Neu5Gc-containing glycan targets, analysis of binding properties of antibodies in sera were further tested and validated in more breast cancer patients. The four most significant glycans were also able to differentiate between controls and patients with various carcinomas including prostate, ovary, endometrium, colon, lung, and pancreas (73). These findings suggest that anti-Neu5Gc antibodies can function as tumor markers. Notably one of the most significant cancer-associated epitopes was very similar to the known sialyl-Tn tumor antigen, except that Neu5Gc replaced Neu5Ac (73). A caveat to the use of glycan microarrays is that interpretation of the results should take into consideration the differences in producing, presenting, coupling, and detecting the glycans (128). Anti-Neu5Gc antibodies can also be analyzed by using Neu5Gc-rich natural


glycoproteins (such as wild type mouse serum) or by coupling glycans to polymers such as polyacrylamide and probing with antibodies on an ELISA plate (72, 86). This less expensive, simpler method could be used as a screening tool, perhaps to monitor disease progression and/or therapeutic response. However, dilution effects on antibody binding and competition between different antibody classes also complicate such studies, and caution must be taken to avoid reagents of animal origin that might introduce Neu5Gc contamination. Population studies are necessary to identify correlations between anti-Neu5Gc antibody levels and carcinoma risk and progression.

IMPLICATIONS FOR CANCER PREVENTION AND TREATMENT

Given the evidence for Neu5Gc in human tissues along with circulating anti-Neu5Gc antibodies, the observed xenosialitis in mouse models could potentially play an important role in the development of cancer (59). Since the source of this foreign sialic acid is the diet, avoidance of Neu5Gc-rich food could possibly reduce cancer risk. Indeed, as discussed above, Neu5Gc-rich red meat increases the risk of inflammation-induced cancers including CRC (89) and our proposed xenosialitis model could be replicating this increased risk. Furthermore, the data predict that the reduction of Neu5Gc consumption could also be important during therapy of already established malignancies in order to interfere with cancer progression. Indeed, high intake of a “western” dietary pattern, rich in red meat, was associated with a higher risk of recurrence and mortality among patients with stage III colon cancer treated with surgery and adjuvant chemotherapy (129).

It is well described that tumor cells are aberrantly sialylated and that content of sialic acid on the surface of tumor cells significantly increase as compared to cells in healthy tissues (130, 131). The up-regulation of sialylation might also explain why ingested Neu5Gc preferentially accumulates in cancer tissues (58, 67). Aberrant sialylation includes an increase of the tumor antigen sialyl-Tn (132–136), which is uncommon in normal tissues (132, 137, 138) or cryptic due to O-acetylation of the sialic acid (133) in healthy tissue. As discussed before, analysis of anti-Neu5Gc antibodies by a sialoglycan microarray showed significant up-regulation of antibodies targeting Neu5Gc-sialyl-Tn suggesting that such antibodies might function as specific tumor biomarkers (73). If this epitope is indeed a relatively cancer-specific antigen, it could be potentially useful as a target for imaging as well as a therapeutic tool for drug delivery. As *in vitro* assays have shown that human antibodies purified from IVIG preparations against Neu5Gc-Tn antigen can activate antibody-dependent cellular and complement-dependent cytotoxicity (ADCC and CDC) (73), the epitope could potentially be directly targeted by anti-Neu5Gc-Tn antibodies.

Neu5Gc-containing gangliosides including GM3 were originally described as an epitope for H-D antibodies (4, 5) and (Neu5Gc)GM3 was found to be a tumor-associated antigen particularly in skin and breast cancer (139, 140). Vaccination with (Neu5Gc)GM3 along with the outer membrane protein complex of *Neisseria meningitidis* in proteoliposomes lead to antibody production in advanced stage breast cancer patients in a phase I study (141). Immunization of mice with (Neu5Gc)GM3 led to the isolation of specific antibody 14F7 (140), which was recently humanized and named racotumumab (142, 143). This



monoclonal antibody is able to bind several malignant tissues including skin cancers, neuroectodermal tumors, genitourinary cancer, non-small cell lung cancer, and tumors of the gastrointestinal tract (144–148). Trials testing the efficacy of racotumumab are currently recruiting (e.g., NCT01598454, NCT01460472). But there is no attempt to control for dietary Neu5Gc intake by patients.

Similar approaches might be taken toward other Neu5Gc-glycan epitopes that are enriched in tumors. For example, vaccination with proteins containing Neu5Gc as terminal sugars could potentially boost an immune response against established tumors. For instance, self-assembling MUC1 with Neu5Gc-Tn antigen could be used to immunize patients with carcinomas (149, 150).

Notably, Neu5Gc is present as a component of some cancer therapeutic agents. Immunotherapy with monoclonal antibodies against other tumor epitopes such as targeting HER2 with trastuzumab, EGF receptor 1 with cetuximab, or CD20 with rituximab are well integrated in today's cancer therapies (151). Antibodies are glycosylated and biotechnological production of such glycoproteins can involve Neu5Gc-rich media and/or non-human cells expressing Neu5Gc (152). Thus, it was previously shown that incorporation of Neu5Gc in cetuximab enhanced the formation of immune complexes and promoted drug clearance (153). Moreover, *Cmah*^{-/-} mice injected with cetuximab reacted with an anti-Neu5Gc immune response (153). Thus, avoidance of Neu5Gc during production of glycoproteins might improve half-life of therapeutics and also reduce the immunogenicity and therefore has important implications in cancer therapy.

CONCLUSIONS AND FUTURE DIRECTIONS

We have discussed the incorporation of the non-human sialic acid Neu5Gc into human tissues, and its potential impact on cancer initiation and progression. We particularly emphasized the

Table 2 | Timeline of discoveries/studies concerning Neu5Gc and anti-Neu5Gc antibodies.

Year(s)	Discoveries/studies	Reference
1924	Discovery of H–D antibodies in patients with serum-sickness	(1, 2)
1970–1980s	Association of H–D antibodies with multiple pathological states, including cancer	(3, 6–9)
1977–1978	Definition of Neu5Gc as key component of H–D antigen	(5)
1980s	Neu5Gc detected in human meconium and carcinomas by immunohistochemistry or TLC; assumed to be an “oncofetal” antigen	(10, 18–22)
1998	Human deficiency of Neu5Gc synthesis due to <i>CMAH</i> inactivation	(46–48)
2003	First results of trial with vaccine containing GM3 (Neu5Gc)	(141)
2003	Metabolic incorporation of Neu5Gc in human tissues from dietary sources	(58)
2003	Neu5Gc is enriched in red meats	(58)
2003	Anti-Neu5Gc response is universal to humans	(58, 71, 72)
2005	Molecular mechanisms of uptake and incorporation of Neu5Gc into cells elucidated – role of macropinocytosis and lysosomal sialin transporter noted	(61)
2006	Up-regulation of the sialin transporter in response to hypoxia in cancer increases Neu5gc accumulation	(127)
2007	Development of <i>Cmah</i> ^{−/−} mouse model. No alternate pathway for Neu5Gc synthesis	(66)
2008	Passively transferred anti-Neu5Gc antibodies enhance <i>Cmah</i> -positive carcinoma progression in <i>Cmah</i> ^{−/−} mice	(59)
2010	Origin of anti-Neu5Gc antibodies via “xeno-autoimmunization” by commensal bacteria that incorporate diet-derived Neu5Gc	(86)
2011	Humanized anti-Neu5Gc-GM3 antibody racotumumab, first trials using this antibody start recruiting	(143)
2011	Neu5Gc-sialyl Tn as potential biomarker cancer biomarker	(73)
2012	Oral glycosidically linked bound Neu5Gc preferentially incorporated into <i>Cmah</i> ^{−/−} mouse tissues, fetuses, and orthotopic tumors	(67)
2012	Intracellular degradative pathway for Neu5Gc discovered	(68)
2013	Simple method for assessment of human anti-Neu5Gc antibodies	(154)

See text for discussion.

resulting inflammatory activation or xenosialitis induced by xeno-autoantibodies against Neu5Gc-containing epitopes (**Figure 3**). Notably, Neu5Gc can also be incorporated into glycans of endothelial cells in healthy individuals and the subsequent xenosialitis has been potentially implicated in the pathogenesis and progression of atherosclerosis (85). Additionally, screening of antibody specificity by Neu5Ac/Neu5Gc specific sialoglycan microarray revealed a Neu5Gc antibody response in children with Kawasaki disease suggesting a possible role of these antibodies in disease progression (154). All these findings support the hypothesis that xenosialitis may be involved in various inflammatory diseases. Thus, avoidance of the Neu5Gc by reducing the consumption of Neu5Gc-containing food could not only have a major impact on the prevention of malignant diseases, but also potentially reduce the risk of cardiovascular disorders. Furthermore, examination and cloning of human anti-Neu5Gc xeno-autoantibodies can provide information about the nature of the anti-Neu5Gc immune response and offer ways to manipulate this in order to produce more efficient vaccines against Neu5Gc-containing tumor-associated epitopes.

Further analysis is needed to determine the pathways by which Neu5Gc is absorbed and transported to healthy and cancerous tissues, in order to be able to interfere with pathological consequences of Neu5Gc incorporation. Since Neu5Gc uses the same biochemical pathways as Neu5Ac, Neu5Gc could be potentially “flushed” out of the body by high amounts of Neu5Ac. The relatively specific accumulation of Neu5Gc on glycans of tumor cells, in particular as Neu5Gc-Tn antigen and (Neu5Gc)GM3 ganglioside is particularly intriguing and should be further studied to harness tumor cells for therapeutic and diagnostic purposes. However, it must be carefully determined if anti-Neu5Gc antibodies are well suited for immunotherapy of tumors or if there are “off-target” effects due to the presence of Neu5Gc-containing epitopes in other tissues. The accumulation of Neu5Gc-containing glycans in tumors in *Cmah*^{−/−} mice fed with the monosaccharide Neu5Gc (67) suggests another strategy of deliberately loading tumors in a selective fashion in order to subsequently target them. Such “loading” of tumor tissue with Neu5Gc might be optimally combined with monoclonal antibody immunotherapies. Finally, it remains to be seen if the increase of Neu5Gc-containing sialoglycans on

the surface of cancer cells might directly influence the cell intrinsic properties such as response to hypoxia or signaling through glycosylated surface receptors.

While much more work is needed to prove or disprove the overall hypothesis, it is encouraging that a prominent textbook of cancer biology has designated this as an “area to watch” (155). But major milestones of progress in the field are likely to be slow. While we are not assuming a similar level of importance to disease pathogenesis, it is instructive to compare the progress to date (Table 2) with those underlying the seminal discovery that cholesterol played a key role in atherosclerosis progression and risk (156). Cholesterol was found in atherosclerotic plaques in 1910, familial hypercholesterolemia was associated with early heart attacks in 1949, and population studies showed an association of heart disease with cholesterol levels by the early 1960s. However two more decades followed before cholesterol lowering by statins was shown to reduce heart attacks and another decade passed before a large scale double-blinded statin trial showed a positive effect in 1994 (156). While studies have clearly shown that Neu5Gc is a tumor-associated antigen with diagnostic and therapeutic potential and mouse models have established the role of xenosialitis in tumor progression, fundamental questions remain unanswered. Can anti-Neu5Gc antibodies and/or Neu5Gc tissue load predict carcinoma risk in human population studies? Will lowering Neu5Gc load reduce carcinoma risk? Is it possible to eliminate the foreign Neu5Gc from tissues or perhaps interfere with the metabolic incorporation process? Considering the potential impact on the prevention and treatment of human disease, it is evident that Neu5Gc and its interactions warrant further experimental and translational investigation.

ACKNOWLEDGMENTS

We thank Frederico Alisson Silva, Anne Bergfeld, and Yuko Naito-Matsui for critical reading of the manuscript and helpful suggestions. Supported by NIH grant CA38701.

REFERENCES

- Hanganutziu M. Hémagglutinines hétérogénétiques après injection de sérum de cheval. *CR Séances Soc Biol* (1924) **91**:1457–9.
- Deicher H. Über die Erzeugung heterospezifischer Hämagglutinine durch Injektion artfremden. *Serums Z Hyg* (1926) **106**:561–79. doi:10.1007/BF02176298
- Kasukawa R, Kano K, Bloom ML, Milgrom F. Heterophile antibodies in pathologic human sera resembling antibodies stimulated by foreign species sera. *Clin Exp Immunol* (1976) **25**:122–32.
- Higashi H, Naiki M, Matuo S, Okouchi K. Antigen of “serum sickness” type of heterophile antibodies in human sera: identification as gangliosides with N-glycolylneuraminic acid. *Biochem Biophys Res Commun* (1977) **79**:388–95. doi:10.1016/0006-291X(77)90169-3
- Merrick JM, Zadarlik K, Milgrom F. Characterization of the Hanganutziu-Deicher (serum-sickness) antigen as gangliosides containing N-glycolylneuraminic acid. *Int Arch Allergy Appl Immunol* (1978) **57**:477–80. doi:10.1159/000232140
- Nishimaki T, Kano K, Milgrom F. Studies on heterophile antibodies in rheumatoid arthritis. *Arthritis Rheum* (1978) **21**:634–8. doi:10.1002/art.1780210604
- Nishimaki T, Kano K, Milgrom F. Studies on immune complexes in rheumatoid arthritis. *Arthritis Rheum* (1978) **21**:639–44. doi:10.1002/art.1780210605
- Nishimaki T, Kano K, Milgrom F. Hanganutziu-Deicher antigen and antibody in pathologic sera and tissues. *J Immunol* (1979) **122**:2314–8.
- Morito T, Kano K, Milgrom F. Hanganutziu-Deicher antibodies in infectious mononucleosis and other diseases. *J Immunol* (1982) **129**:2524–8.
- Ikuta K, Nishi Y, Shimizu Y, Higashi H, Kitamoto N, Kato S, et al. Hanganutziu-Deicher type-heterophile antigen-positive cells in human cancer tissues demonstrated by membrane immunofluorescence. *Biken J* (1982) **25**:47–50.
- Arita K, Ikuta K, Nishi Y, Kato S, Yamauchi E, Maki S, et al. Heterophile Hanganutziu-Deicher antibodies in sera of patients with Kawasaki diseases. *Biken J* (1982) **25**:157–62.
- Takiguchi M, Tamura T, Goto M, Kusakawa S, Milgrom F, Kano K. Immunological studies on Kawasaki disease. I. Appearance of Hanganutziu-Deicher antibodies. *Clin Exp Immunol* (1984) **56**:345–52.
- Mukuria JC, Naiki M, Hashimoto M, Kato S. A specific enzyme-linked immunosorbent assay (ELISA) procedure for detection of heterophile Hanganutziu and Deicher (HD) antibodies. *J Immunol Methods* (1986) **86**:179–85. doi:10.1016/0022-1759(86)90450-3
- Mukuria CJ, Fujii Y, Kato S, Naiki M. Specificities of human heterophile Hanganutziu and Deicher (HD) antibodies to glycosphingolipids and a glycoprotein. *J Biochem* (1986) **100**:469–75.
- Morito T, Nishimaki T, Masaki M, Yoshida H, Kasukawa R, Nakarai H, et al. Studies on Hanganutziu-Deicher antigens-antibodies. I Hanganutziu-Deicher antibodies of IgG class in liver diseases. *Int Arch Allergy Appl Immunol* (1986) **81**:204–8. doi:10.1159/000234135
- Nakarai H, Saïda T, Shibata Y, Irie RF, Kano K. Expression of heterophile, Paul-Bunnell and Hanganutziu-Deicher antigens on human melanoma cell lines. *Int Arch Allergy Appl Immunol* (1987) **83**:160–6. doi:10.1159/000234349
- Higashihara T, Takeshima T, Anzai M, Tomioka M, Matsumoto K, Nishida K, et al. Survey of Hanganutziu and Deicher antibodies in operated patients. *Int Arch Allergy Appl Immunol* (1991) **95**:231–5. doi:10.1159/000235434
- Ohashi Y, Sasabe T, Nishida T, Nishi Y, Higashi H. Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells. *Am J Ophthalmol* (1983) **96**:321–5.
- Higashi H, Fukui Y, Ueda S, Kato S, Hirabayashi Y, Matsumoto M, et al. Sensitive enzyme-immunostaining and densitometric determination on thin-layer chromatography of N-glycolylneuraminic acid-containing glycosphingolipids, Hanganutziu-Deicher antigens. *J Biochem* (1984) **95**:1517–20.
- Higashi H, Nishi Y, Fukui Y, Ikuta K, Ueda S, Kato S, et al. Tumor-associated expression of glycosphingolipid Hanganutziu-Deicher antigen in human cancers. *Gann* (1984) **75**:1025–9.
- Mukuria JC, Naiki M, Hashimoto M, Nishiura K, Okabe M, Kato S. A potential radioimmunoassay system for detection of Hanganutziu-Deicher type heterophile antigen(s) and antibodies in tissues and fluids. *J Immunol Methods* (1985) **80**:97–106. doi:10.1016/0022-1759(85)90168-1
- Higashi H, Hirabayashi Y, Fukui Y, Naiki M, Matsumoto M, Ueda S, et al. Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer. *Cancer Res* (1985) **45**:3796–802.
- Nowak JA, Jain NK, Stinson MW, Merrick JM. Interaction of bovine erythrocyte N-glycolylneuraminic acid-containing gangliosides and glycoproteins with a human Hanganutziu-Deicher serum. *Mol Immunol* (1986) **23**:693–700. doi:10.1016/0161-5890(86)90079-9
- Mukuria JC, Naiki M, Kato S. Microstructure of the sialic acid moiety of N-glycolylneuraminylactosylceramide and the elucidation of Hanganutziu and Deicher (HD) antigenicity. *Immunol Lett* (1986) **12**:165–9.
- Hirabayashi Y, Higashi H, Kato S, Taniguchi M, Matsumoto M. Occurrence of tumor-associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas. *Jpn J Cancer Res* (1987) **78**:614–20.
- Hirabayashi Y, Kasakura H, Matsumoto M, Higashi H, Kato S, Kasai N, et al. Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers. *Jpn J Cancer Res* (1987) **78**:251–60.
- Higashi H, Sasabe T, Fukui Y, Maru M, Kato S. Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. *Jpn J Cancer Res* (1988) **79**:952–6. doi:10.1111/j.1349-7006.1988.tb00060.x
- Kawachi S, Saïda T, Uhara H, Uemura K, Taketomi T, Kano K. Heterophile Hanganutziu-Deicher antigen in ganglioside fractions of human melanoma tissues. *Int Arch Allergy Appl Immunol* (1988) **85**:381–3. doi:10.1159/000234536
- Fukui Y, Maru M, Ohkawara K, Miyake T, Osada Y, Wang DQ, et al. Detection of glycoproteins as tumor-associated Hanganutziu-Deicher antigen in human gastric cancer cell line, NUGC4. *Biochem Biophys Res Commun* (1989) **160**:1149–54. doi:10.1016/S0006-291X(89)80123-8

30. Nakarai H, Chandler PJ, Kano K, Morton DL, Irie RF. Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma. *Int Arch Allergy Appl Immunol* (1990) **91**:323–8. doi:10.1159/000235135
31. Saida T, Ikegawa S, Takizawa Y, Kawachi S. Immunohistochemical detection of heterophile Hanganutziu-Deicher antigen in human malignant melanoma. *Arch Dermatol Res* (1990) **282**:179–82. doi:10.1007/BF00372619
32. Kawachi S, Saida T. Analysis of the expression of Hanganutziu-Deicher (HD) antigen in human malignant melanoma. *J Dermatol* (1992) **19**:827–30.
33. Schauer R. Sialic acids as regulators of molecular and cellular interactions. *Curr Opin Struct Biol* (2009) **19**:507–14. doi:10.1016/j.sbi.2009.06.003
34. Varki A. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. *Nature* (2007) **446**:1023–9. doi:10.1038/nature05816
35. Varki A, Schauer R. Sialic acids. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. *Essentials of Glycobiology*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2009). p. 199–218.
36. Chen X, Varki A. Advances in the biology and chemistry of sialic acids. *ACS Chem Biol* (2010) **5**:163–76. doi:10.1021/cb900266r
37. Schauer R, Schoop HJ, Faillard H. On biosynthesis of the glycolyl groups of N-glycolylneuraminic acid oxidative conversion of N-acetyl groups to glycolyl groups. *Hoppe Seylers Z Physiol Chem* (1968) **349**:645–52. doi:10.1515/bchm2.1968.349.1.645
38. Buscher HP, Casals SJ, Schauer R, Mestres VP. Biosynthesis of N-glycolylneuraminic acid in porcine submandibular glands. Subcellular site of hydroxylation of N-acetylneuraminic acid in the course of glycoprotein biosynthesis. *Eur J Biochem* (1977) **77**:297–310. doi:10.1111/j.1432-1033.1977.tb11668.x
39. Shaw L, Schauer R. The biosynthesis of N-glycolylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid. *Biol Chem Hoppe Seyler* (1988) **369**:477–86. doi:10.1515/bchm3.1988.369.1.477
40. Muchmore EA, Milewski M, Varki A, Diaz S. Biosynthesis of N-glycolylneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool. *J Biol Chem* (1989) **264**:20216–23.
41. Kozutsumi Y, Kawano T, Kawasaki H, Suzuki K, Yamakawa T, Suzuki A. Reconstitution of CMP-N-acetylneuraminic acid hydroxylation activity using a mouse liver cytosol fraction and soluble cytochrome b5 purified from horse erythrocytes. *J Biochem* (1991) **110**:429–35.
42. Shaw L, Schneckeburger P, Carlsen J, Christiansen K, Schauer R. Mouse liver cytidine-5'-monophosphate-N-acetylneuraminic acid hydroxylase – catalytic function and regulation. *Eur J Biochem* (1992) **206**:269–77. doi:10.1111/j.1432-1033.1992.tb16925.x
43. Kawano T, Kozutsumi Y, Takematsu H, Kawasaki T, Suzuki A. Regulation of biosynthesis of N-glycolylneuraminic acid-containing glycoconjugates: characterization of factors required for NADH-dependent cytidine 5'-monophosphate-N-acetylneuraminic acid hydroxylation. *Glycoconj J* (1993) **10**:109–15. doi:10.1007/BF00731194
44. Kawano T, Koyama S, Takematsu H, Kozutsumi Y, Kawasaki H, Kawashima S, et al. Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolylneuraminic acid. *J Biol Chem* (1995) **270**:16458–63. doi:10.1074/jbc.270.27.16458
45. Shaw L, Schauer R. Detection of CMP-N-acetylneuraminic acid hydroxylase activity in fractionated mouse liver. *Biochem J* (1989) **263**:355–63.
46. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. *Proc Natl Acad Sci U S A* (1998) **95**:11751–6. doi:10.1073/pnas.95.20.11751
47. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. *J Biol Chem* (1998) **273**:15866–71. doi:10.1074/jbc.273.25.15866
48. Hayakawa T, Satta Y, Gagneux P, Varki A, Takahata N. Alu-mediated inactivation of the human CMP-N-acetylneuraminic acid hydroxylase gene. *Proc Natl Acad Sci U S A* (2001) **98**:11399–404. doi:10.1073/pnas.191268198
49. Varki A, Gagneux P. Human-specific evolution of sialic acid targets: explaining the malignant malaria mystery? *Proc Natl Acad Sci U S A* (2009) **106**:14739–40. doi:10.1073/pnas.0908196106
50. Ghaderi D, Springer SA, Ma F, Cohen M, Secrest P, Taylor RE, et al. Sexual selection by female immunity against paternal antigens can fix loss of function alleles. *Proc Natl Acad Sci U S A* (2011) **108**:17743–8. doi:10.1073/pnas.1102302108
51. Varki A. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. *Proc Natl Acad Sci U S A* (2010) **107**(Suppl 2):8939–46. doi:10.1073/pnas.0914634107
52. Wang X, Mitra N, Cruz P, Deng L; NISC Comparative Sequencing Program, Varki N, et al. Evolution of siglec-11 and siglec-16 genes in hominins. *Mol Biol Evol* (2012) **29**(8):2073–86. doi:10.1093/molbev/mss077
53. Schauer R, Srinivasan GV, Coddeville B, Zanetta JP, Guerardel Y. Low incidence of N-glycolylneuraminic acid in birds and reptiles and its absence in the platypus. *Carbohydr Res* (2009) **344**:1494–500. doi:10.1016/j.carres.2009.05.020
54. Fujii Y, Higashi H, Ikuta K, Kato S, Naiki M. Specificities of human heterophilic Hanganutziu and Deicher (H-D) antibodies and avian antisera against H-D antigen-active glycosphingolipids. *Mol Immunol* (1982) **19**:87–94.
55. Miyoshi I, Fujii Y, Naiki M. Avian antisera to various gangliosides: detection by enzyme immunoassay. *J Biochem* (1982) **92**:89–94.
56. Naiki M, Fujii Y, Ikuta K, Higashi H, Kato S. Expression of Hanganutziu and Deicher type heterophile antigen on the cell surface of Marek's disease lymphoma. *Adv Exp Med Biol* (1982) **152**:445–56.
57. Higashi H, Ikuta K, Ueda S, Kato S, Hirabayashi Y, Matsumoto M, et al. Characterization of N-glycolylneuraminic acid-containing glycosphingolipids from a Marek's disease lymphoma-derived chicken cell line, MSB1, as tumor-associated heterophile Hanganutziu-Deicher antigens. *J Biochem* (1984) **95**:785–94.
58. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. *Proc Natl Acad Sci U S A* (2003) **100**:12045–50. doi:10.1073/pnas.2131556100
59. Hedlund M, Padler-Karavani V, Varki NM, Varki A. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. *Proc Natl Acad Sci U S A* (2008) **105**:18936–41. doi:10.1073/pnas.0803943105
60. Chen Y, Pan L, Liu N, Troy FA, Wang B. LC-MS/MS quantification of N-acetylneuraminic acid, N-glycolylneuraminic acid and ketodeoxynonulosonic acid levels in the urine and potential relationship with dietary sialic acid intake and disease in 3- to 5-year-old children. *Br J Nutr* (2014) **111**(2):332–41. doi:10.1017/S0007114513002468
61. Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. *J Biol Chem* (2005) **280**:4228–37. doi:10.1074/jbc.M412040200
62. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. *J Immunol* (2005) **175**:228–36.
63. Nohle U, Beau JM, Schauer R. Uptake, metabolism and excretion of orally and intravenously administered, double-labeled N-glycolylneuraminic acid and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat. *Eur J Biochem* (1982) **126**:543–8. doi:10.1111/j.1432-1033.1982.tb06815.x
64. Nohle U, Schauer R. Uptake, metabolism and excretion of orally and intravenously administered, ¹⁴C- and ³H-labeled N-acetylneuraminic acid mixture in the mouse and rat. *Hoppe Seylers Z Physiol Chem* (1981) **362**:1495–506. doi:10.1515/bchm2.1981.362.2.1495
65. Nohle U, Schauer R. Metabolism of sialic acids from exogenously administered sialyllactose and mucin in mouse and rat. *Hoppe Seylers Z Physiol Chem* (1984) **365**:1457–67. doi:10.1515/bchm2.1984.365.2.1457
66. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, Kozutsumi Y, et al. N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. *Mol Cell Biol* (2007) **27**:4340–6. doi:10.1128/MCB.00379-07
67. Banda K, Gregg CJ, Chow R, Varki NM, Varki A. Metabolism of vertebrate amino sugars with N-glycolyl groups: mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid. *J Biol Chem* (2012) **287**:28852–64. doi:10.1074/jbc.M112.364182
68. Bergfeld AK, Pearce OM, Diaz SL, Pham T, Varki A. Metabolism of vertebrate amino sugars with N-glycolyl groups: elucidating the intracellular fate of the non-human sialic acid N-glycolylneuraminic acid. *J Biol Chem* (2012) **287**:28865–81. doi:10.1074/jbc.M112.363549
69. Vamecq J, Poupaert JH. Studies on the metabolism of glycolyl-CoA. *Biochem Cell Biol* (1990) **68**:846–51. doi:10.1139/o90-125

70. Vamecq J, Mestdagh N, Henichart J-P, Poupaert J. Subcellular distribution of glycolyltransferases in rodent liver and their significance in special reference to the synthesis of N-glycolylneuraminic acid. *J Biochem* (1992) **111**:579–83.
71. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. *Xenotransplantation* (2002) **9**:376–81. doi:10.1034/j.1399-3089.2002.02138.x
72. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. *Glycobiology* (2008) **18**:818–30. doi:10.1093/glycob/cwn072
73. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, et al. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. *Cancer Res* (2011) **71**:3352–63. doi:10.1158/0008-5472.CAN-10-4102
74. Asaoka H, Nishinaka S, Wakamiya N, Matsuda H, Murata M. Two chicken monoclonal antibodies specific for heterophil Hanganutziu-Deicher antigens. *Immunol Lett* (1992) **32**:91–6.
75. Malakh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in human tumours. *Biochimie* (2001) **83**:623–34. doi:10.1016/S0300-9084(01)01303-7
76. Iznaga N, Carr A, Fernández LE, Solozabal J, Núñez G, Perdomo Y, et al. Amplified ELISA to detect autoantibodies to N-glycolyl-GM3 ganglioside. *J Clin Lab Immunol* (1996) **48**:75–85.
77. Padlan EA, Kabat EA. Model-building study of the combining sites of two antibodies to alpha(1–6)dextran. *Proc Natl Acad Sci U S A* (1988) **85**:6885–9. doi:10.1073/pnas.85.18.6885
78. Chang WW, Yu CY, Lin TW, Wang PH, Tsai YC. Soyasaponin I decreases the expression of alpha2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. *Biochem Biophys Res Commun* (2006) **341**:614–9. doi:10.1016/j.bbrc.2005.12.216
79. Yu H, Chokhawala HA, Varki A, Chen X. Efficient chemoenzymatic synthesis of biotinylated human serum albumin-sialoglycoside conjugates containing O-acetylated sialic acids. *Org Biomol Chem* (2007) **5**:2458–63. doi:10.1039/b706507h
80. Usuba O, Fujii Y, Miyoshi I, Naiki M, Sendo F. Establishment of a human monoclonal antibody to Hanganutziu-Deicher antigen as a tumor-associated carbohydrate antigen. *Jpn J Cancer Res* (1988) **79**:1340–8. doi:10.1111/j.1349-7006.1988.tb01565.x
81. Sanai Y, Yamasaki M, Nagai Y. Monoclonal antibody directed to a Hanganutziu-Deicher active ganglioside, GM2 (NeuGc). *Biochim Biophys Acta* (1988) **958**:368–74. doi:10.1016/0005-2760(88)90222-6
82. Asaoka H, Matsuda H. Detection of N-glycolylneuraminic acid-containing glycoproteins from various animal erythrocytes by chicken monoclonal antibody against Hanganutziu-Deicher antigens. *J Vet Med Sci* (1994) **56**:375–7. doi:10.1292/jvms.56.375
83. Koda T, Shimosakoda T, Nishinaka S, Asaoka H, Nakaba H, Tamura I, et al. Diagnosis of hepatocellular carcinoma using chicken anti-monoclonal antibody – as tumor marker on the heterophilic Hanganutziu-Deicher antigen. *Gan To Kagaku Ryoho* (1994) **21**:2771–7.
84. Watarai S, Kushi Y, Shigeto R, Misawa N, Eishi Y, Handa S, et al. Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides. *J Biochem* (1995) **117**:1062–9.
85. Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, Cao H, et al. Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. *Blood* (2009) **114**:5225–35. doi:10.1182/blood-2009-05-220400
86. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, et al. Novel mechanism for the generation of human xeno-autoantibodies against the non-human sialic acid N-glycolylneuraminic acid. *J Exp Med* (2010) **207**:1637–46. doi:10.1084/jem.20100575
87. Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Willett WC, et al. Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. *Am J Clin Nutr* (2011) **94**:1088–96. doi:10.3945/ajcn.111.018978
88. Micha R, Wallace SK, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. *Circulation* (2010) **121**:2271–83. doi:10.1161/CIRCULATIONAHA.109.924977
89. Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Stampfer MJ, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. *Arch Intern Med* (2012) **172**:555–63. doi:10.1001/archinternmed.2011.2287
90. World Cancer Research Fund International. *Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective*. Washington, DC: American Institute for Cancer Research (2007).
91. Gonzalez CA, Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. *Eur J Cancer* (2010) **46**:2555–62. doi:10.1016/j.ejca.2010.07.025
92. Arem H, Gunter MJ, Cross AJ, Hollenbeck AR, Sinha R. A prospective investigation of fish, meat and cooking-related carcinogens with endometrial cancer incidence. *Br J Cancer* (2013) **109**:756–60. doi:10.1038/bjc.2013.252
93. Salehi M, Moradi-Lakeh M, Salehi MH, Nojomi M, Kolahdooz F. Meat, fish, and esophageal cancer risk: a systematic review and dose-response meta-analysis. *Nutr Rev* (2013) **71**:257–67. doi:10.1111/nure.12028
94. Zhu H, Yang X, Zhang C, Zhu C, Tao G, Zhao L, et al. Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. *PLoS One* (2013) **8**:e70955. doi:10.1371/journal.pone.0070955
95. Hori S, Butler E, McLoughlin J. Prostate cancer and diet: food for thought? *BJU Int* (2011) **107**:1348–59. doi:10.1111/j.1464-410X.2010.09897.x
96. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. *Cancer Res* (1994) **54**:2390–7.
97. Stavric B. Biological significance of trace levels of mutagenic heterocyclic aromatic amines in human diet: a critical review. *Food Chem Toxicol* (1994) **32**:977–94. doi:10.1016/0278-6915(94)90093-0
98. Santarelli RL, Pierre F, Corpet DE. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. *Nutr Cancer* (2008) **60**:131–44. doi:10.1080/01635580701684872
99. Bastide NM, Pierre FH, Corpet DE. Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved. *Cancer Prev Res (Phila)* (2011) **4**:177–84. doi:10.1158/1940-6207.CAPR-10-0113
100. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med* (2013) **19**:576–85. doi:10.1038/nm.3145
101. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med* (2013) **368**:1575–84. doi:10.1056/NEJMoa1109400
102. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. *Am J Clin Nutr* (2004) **80**:1029–35.
103. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. *Lancet* (2008) **371**:771–83. doi:10.1016/S0140-6736(08)60241-X
104. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoeediting: integrating immunity's roles in cancer suppression and promotion. *Science* (2011) **331**:1565–70. doi:10.1126/science.1203486
105. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. *Annu Rev Immunol* (1994) **12**:337–65.
106. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature* (2011) **480**:480–9. doi:10.1038/nature10673
107. Pardoll D. Does the immune system see tumors as foreign or self? *Annu Rev Immunol* (2003) **21**:807–39.
108. Finn OJ. Cancer immunology. *N Engl J Med* (2008) **358**:2704–15. doi:10.1056/NEJMr072739
109. Coussens LM, Werb Z. Inflammation and cancer. *Nature* (2002) **420**:860–7. doi:10.1038/nature01322
110. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* (2012) **21**:309–22. doi:10.1016/j.ccr.2012.02.022
111. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* (2009) **9**:162–74. doi:10.1038/nri2506
112. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* (2013) **369**(2):122–33. doi:10.1056/NEJMoa1302369

113. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. *Nat Rev Immunol* (2012) **12**:269–81. doi:10.1038/nri3191
114. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. *Proc Natl Acad Sci U S A* (2004) **101**(Suppl 2):14639–45. doi:10.1073/pnas.0405730101
115. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? *Science* (2013) **339**:286–91. doi:10.1126/science.1232227
116. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* (2001) **357**:539–45. doi:10.1016/S0140-6736(00)04046-0
117. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell* (2010) **140**:883–99. doi:10.1016/j.cell.2010.01.025
118. Wang D, DuBois RN. Inflammatory mediators and nuclear receptor signaling in colorectal cancer. *Cell Cycle* (2007) **6**:682–5. doi:10.4161/cc.6.6.4030
119. Rothwell PM, Fowkes FG, Belch JE, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* (2011) **377**:31–41. doi:10.1016/S0140-6736(10)62110-1
120. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat Rev Cancer* (2001) **1**:11–21. doi:10.1038/35094017
121. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. *Lancet* (2009) **373**:1301–9. doi:10.1016/S0140-6736(09)60243-9
122. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* (2008) **454**:436–44. doi:10.1038/nature07205
123. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer* (2009) **9**:239–52. doi:10.1038/nrc2618
124. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. *Nat Rev Cancer* (2009) **9**:285–93. doi:10.1038/nrc2621
125. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell* (2013) **23**:277–86. doi:10.1016/j.ccr.2013.02.013
126. Varki A, Kannagi R, Toole BP. Glycosylation changes in cancer. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. *Essentials of Glycobiology*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2009). p. 617–32.
127. Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen GY, Takematsu H, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. *Cancer Res* (2006) **66**:2937–45. doi:10.1158/0008-5472.CAN-05-2615
128. Padler-Karavani V, Song X, Yu H, Hurtado-Ziola N, Huang S, Muthana S, et al. Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. *J Biol Chem* (2012) **287**:22593–608. doi:10.1074/jbc.M112.359323
129. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. *JAMA* (2007) **298**:754–64. doi:10.1001/jama.298.7.754
130. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. *Immunity* (2012) **36**:322–35. doi:10.1016/j.immuni.2012.03.004
131. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. *Nat Rev Cancer* (2005) **5**:526–42. doi:10.1038/nrc1649
132. Yonezawa S, Tachikawa T, Shin S, Sato E. Sialosyl-Tn antigen. Its distribution in normal human tissues and expression in adenocarcinomas. *Am J Clin Pathol* (1992) **98**:167–74.
133. Ogata S, Koganty R, Reddish M, Longenecker BM, Chen A, Perez C, et al. Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. *Glycoconj J* (1998) **15**:29–35. doi:10.1023/A:1006935331756
134. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. *J Clin Oncol* (1992) **10**:95–101.
135. Imai J, Ghazizadeh M, Naito Z, Asano G. Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma. *Anticancer Res* (2001) **21**:1327–34.
136. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. *Gastroenterology* (2002) **123**:1052–60. doi:10.1053/gast.2002.36018
137. Conze T, Carvalho AS, Landegren U, Almeida R, Reis CA, David L, et al. MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas. *Glycobiology* (2010) **20**:199–206. doi:10.1093/glycob/cwp161
138. Cao Y, Stosiek P, Springer GF, Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. *Histochem Cell Biol* (1996) **106**:197–207. doi:10.1007/BF02484401
139. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. *Cancer Res* (1996) **56**:5165–71.
140. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. *Hybridoma* (2000) **19**:241–7. doi:10.1089/02724570050109639
141. Carr A, Rodríguez E, Arango Mdel C, Camacho R, Osorio M, Gabri M, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. *J Clin Oncol* (2003) **21**:1015–21. doi:10.1200/JCO.2003.02.124
142. Fernández-Marrero Y, Hernández T, Roque-Navarro L, Talavera A, Moreno E, Griñán T, et al. Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. *Mol Immunol* (2011) **48**:1059–67. doi:10.1016/j.molimm.2011.01.008
143. Fernández-Marrero Y, Roque-Navarro L, Hernández T, Dorvignit D, Molina-Pérez M, González A, et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycosylated-glycoconjugates. *Immunobiology* (2011) **216**:1239–47. doi:10.1016/j.imbio.2011.07.004
144. Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, et al. Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. *Clin Dev Immunol* (2011) **2011**:245181. doi:10.1155/2011/245181
145. Scursoni AM, Galluzzo L, Camarero S, Pozzo N, Gabri MR, de Acosta CM, et al. Detection and characterization of N-glycosylated gangliosides in Wilms tumor by immunohistochemistry. *Pediatr Dev Pathol* (2010) **13**:18–23. doi:10.2350/08-10-0544.1
146. Blanco R, Rengifo E, Cedeno M, Rengifo CE, Alonso DE, Carr A. Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. *ISRN Gastroenterol* (2011) **2011**:645641. doi:10.5402/2011/645641
147. Blanco R, Rengifo E, Rengifo CE, Cedeno M, Frometa M, Carr A. Immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-glycolyl GM3 ganglioside in some benign and malignant skin neoplasms. *ISRN Dermatol* (2011) **2011**:848909. doi:10.5402/2011/848909
148. Blanco R, Rengifo CE, Cedeno M, Frometa M, Rengifo E, Carr A. Immunoreactivity of the 14F7 Mab (raised against N-Glycolyl GM3 ganglioside) as a positive prognostic factor in non-small-cell lung cancer. *Patholog Res Int* (2012) **2012**:235418. doi:10.1155/2012/235418
149. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdevint FG, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and N-acetylgalactosamine (GalNAc) peptides. *Int J Cancer* (2000) **86**:702–12. doi:10.1002/(SICI)1097-0215(20000601)86:53:3.CO;2-T
150. Huang ZH, Shi L, Ma JW, Sun ZY, Cai H, Chen YX, et al. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy. *J Am Chem Soc* (2012) **134**:8730–3. doi:10.1021/ja211725s
151. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. *Science* (2013) **341**:1192–8. doi:10.1126/science.1241145
152. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. *Biotechnol Genet Eng Rev* (2012) **28**:147–75. doi:10.5661/bger-28-147
153. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. *Nat Biotechnol* (2010) **28**:863–7. doi:10.1038/nbt.1651
154. Padler-Karavani V, Tremoulet AH, Yu H, Chen X, Burns JC, Varki A. A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. *PLoS One* (2013) **8**:e58443. doi:10.1371/journal.pone.0058443

155. Weinberg RA. *Supplement 11.7 How Does Diet Affect Colon Cancer Incidence? The Biology of Cancer*. New York: Garland Publishing (2014).
156. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. *J Lipid Res* (2006) **47**:1339–51. doi:10.1194/jlr.R600009-JLR200
157. Hirabayashi Y, Suzuki T, Suzuki Y, Taki T, Matsumoto M, Higashi H, et al. A new method for purification of anti-glycosphingolipid antibody. Avian anti-hematoside (NeuGc) antibody. *J Biochem* (1983) **94**:327–30.
158. Diaz SL, Padler-Karavani V, Ghaderi D, Hurtado-Ziola N, Yu H, Chen X, et al. Sensitive and specific detection of the non-human sialic acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. *PLoS One* (2009) **4**:e4241. doi:10.1371/journal.pone.0004241
159. Koda T, Aosasa M, Asaoka H, Nakaba H, Matsuda H. Application of tyramide signal amplification for detection of N-glycolylneuraminic acid in human hepatocellular carcinoma. *Int J Clin Oncol* (2003) **8**:317–21. doi:10.1007/s10147-003-0346-4
160. Miyake M, Ito M, Hitomi S, Ikeda S, Taki T, Kurata M, et al. Generation of two murine monoclonal antibodies that can discriminate N-glycolyl and N-acetyl neuraminic acid residues of GM2 gangliosides. *Cancer Res* (1988) **48**:6154–60.
161. Ozawa H, Kawashima I, Tai T. Generation of murine monoclonal antibodies specific for N-glycolylneuraminic acid-containing gangliosides. *Arch Biochem Biophys* (1992) **294**:427–33. doi:10.1016/0003-9861(92)90707-4
162. Kawashima I, Ozawa H, Kotani M, Suzuki M, Kawano T, Gomibuchi M, et al. Characterization of ganglioside expression in human melanoma cells: immunological and biochemical analysis. *J Biochem* (1993) **114**:186–93.
163. Nakamura K, Suzuki H, Hirabayashi Y, Suzuki A. IV3₂(NeuGc)α2-8NeuGc)-Gg4Cer is restricted to CD4⁺ T cells producing interleukin-2 and a small population of mature thymocytes in mice. *J Biol Chem* (1995) **270**:3876–81. doi:10.1074/jbc.270.8.3876
164. Manzi AE, Diaz S, Varki A. High-pressure liquid chromatography of sialic acids on a pellicular resin anion-exchange column with pulsed amperometric detection: a comparison with six other systems. *Anal Biochem* (1990) **188**:20–32. doi:10.1016/0003-2697(90)90523-C
165. Rohrer JS. Analyzing sialic acids using high-performance anion-exchange chromatography with pulsed amperometric detection. *Anal Biochem* (2000) **283**:3–9. doi:10.1006/abio.2000.4643
166. Hurum DC, Rohrer JS. Five-minute glycoprotein sialic acid determination by high-performance anion exchange chromatography with pulsed amperometric detection. *Anal Biochem* (2011) **419**:67–9. doi:10.1016/j.ab.2011.08.002
167. van der Ham M, Prinsen BH, Huijman JG, Abeling NG, Dorland B, Berger R, et al. Quantification of free and total sialic acid excretion by LC-MS/MS. *J Chromatogr B Anal Technol Biomed Life Sci* (2007) **848**(2):251–7. doi:10.1016/j.jchromb.2006.10.066
168. Allevi P, Femia EA, Costa ML, Cazzola R, Anastasia M. Quantification of N-acetyl- and N-glycolylneuraminic acids by a stable isotope dilution assay using high-performance liquid chromatography-tandem mass spectrometry. *J Chromatogr A* (2008) **1212**:98–105. doi:10.1016/j.chroma.2008.10.039
169. Hara S, Yamaguchi M, Takemori Y, Furuhashi K, Ogura H, Nakamura M. Determination of mono-O-acetylated N-acetylneuraminic acids in human and rat sera by fluorometric high-performance liquid chromatography. *Anal Biochem* (1989) **179**:162–6. doi:10.1016/0003-2697(89)90218-2
170. Lacombe R, Salcedo J, Alegria A, Jesus Lagarda M, Barbera R, Matencio E. Determination of sialic acid and gangliosides in biological samples and dairy products: a review. *J Pharm Biomed Anal* (2010) **51**:346–57. doi:10.1016/j.jpba.2009.04.023
171. Gong S, Ren HL, Tian RY, Lin C, Hu P, Li YS, et al. A novel analytical probe binding to a potential carcinogenic factor of N-glycolylneuraminic acid by SELEX. *Biosens Bioelectron* (2013) **49**:547–54. doi:10.1016/j.bios.2013.05.024

Conflict of Interest Statement: Ajit Varki and Nissi Varki are co-founders of and advisors to Sialix, Inc., which has licensed UCSD technologies related to anti-Neu5Gc antibodies in cancer. The other co-authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 16 January 2014; accepted: 05 February 2014; published online: 19 February 2014.

Citation: Samraj AN, Läubli H, Varki N and Varki A (2014) Involvement of a non-human sialic acid in human cancer. *Front. Oncol.* **4**:33. doi: 10.3389/fonc.2014.00033 This article was submitted to *Molecular and Cellular Oncology*, a section of the journal *Frontiers in Oncology*.

Copyright © 2014 Samraj, Läubli, Varki and Varki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.



Corrigendum: Involvement of a non-human sialic acid in human cancer

Annie N. Samraj, Heinz Läubli, Nissi Varki and Ajit Varki*

Departments of Medicine, Pathology and Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA

*Correspondence: a1varki@ucsd.edu

Edited and reviewed by:

Adriane Regina Todeschini, Universidade Federal do Rio de Janeiro, Brazil

Keywords: Neu5Gc, sialic acid, antibodies, inflammation, tumor antigen, red meat

A corrigendum on

Involvement of a non-human sialic acid in human cancer

by Samraj AN, Läubli H and Varki A. *Front Oncol* (2014) 4:33. doi: 10.3389/fonc.2014.00033

Antibodies 14F7 and the corresponding anti-idiotypic 1E10 (racotumomab, misspelled as racotumumab) were mistakenly conflated in this review. 14F7 reacts with (Neu5Gc)GM3, was recently humanized (1), but has not yet been tested in clinical trials. Racotumomab induced a human anti-(Neu5Gc)GM3 immune response, which correlated with longer median survival in non-small cell lung cancer (2). The first clinical trial result using racotumomab was actually published in 2002 (3). A phase III trial testing racotumomab in advanced non-small cell lung

cancer began in 2011, and is currently recruiting (NCT01460472). These studies do not consider dietary Neu5Gc intake and incorporation as a variable that could affect (Neu5Gc)GM3 expression by human cancers.

REFERENCES

1. Fernández-Marrero Y, Roque-Navarro L, Hernández T, Dorvignit D, Molina-Pérez M, González A, et al. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycosylated-glycoconjugates. *Immunobiology* (2011) 216:1239–47. doi:10.1016/j.imbio.2011.07.004
2. Hernández AM, Toledo D, Martínez D, Griñán T, Brito V, Macías A, et al. Characterization of the antibody response against Neu5GcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotypic antibody. *J Immunol* (2008) 181:6625–34.
3. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, et al. An anti-idiotypic vaccine elicits a specific response to N-glycosyl

sialic acid residues of glycoconjugates in melanoma patients. *J Immunol* (2002) 168:2523–9.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 02 April 2014; accepted: 04 April 2014; published online: 22 April 2014.

Citation: Samraj AN, Läubli H, Varki N and Varki A (2014) Corrigendum: Involvement of a non-human sialic acid in human cancer. *Front. Oncol.* 4:83. doi: 10.3389/fonc.2014.00083

This article was submitted to *Molecular and Cellular Oncology*, a section of the journal *Frontiers in Oncology*. Copyright © 2014 Samraj, Läubli, Varki and Varki. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.